Skip to content

Efficacy of Goreisan in transurethral resection of prostate

Efficacy of Goreisan in transurethral resection of prostate - RCT of Goreisan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017135
Enrollment
60
Registered
2015-04-14
Start date
2015-05-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who undergo transurethral resection of prostate because of benign prostatic hypertrophy

Interventions

intake of Goreisan as a preoperative medication no intake of Goreisan as conventional treatment

Sponsors

Osaka Medical College
Lead Sponsor
Sanko Hoapital (in Takatsuki, Osaka)
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Benign prostatic hypertrophy 2) male: 20-89 year-old 3) patients showed consent of this study

Exclusion criteria

Exclusion criteria: 1) emergency operation 2) simultaneously having different operation 3) serum potassium level <125mmol/l 4) having severe coronary diseases and cerebral vessel diseases 5) having severe liver dysfunctions 6) hyperkalemia 7) hemodialysis 8) permanent pacemaker 9) medication of CYP3A4 inhibitors 10) medication of vasopression related drugs 11) medication of inotropic agents 12) medication of Potassium-sparing diuretics 13) BMI>or=35 14) Coagulation disorder 15) Severe complication with a diagnosis of 6 months remaining 16) Participation in other intervention studies 17) being judged as not appropriate for this study

Design outcomes

Primary

MeasureTime frame
change of serum potassium levels and occurrence of TUR syndrome

Secondary

MeasureTime frame
1) perioperative mortality 2) neurological and circuratory abnormality 3) serum creatinine levels 4) lactate levels

Countries

Japan

Contacts

Public ContactJunko Nakahira

Osaka Medical College Department of Anesthesiology

ane052@osaka-med.ac.jp72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026